CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 8, 2017--
Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage
biopharmaceutical company developing novel medicines to treat
life-altering central nervous system (CNS) disorders, today announced
the addition of Asha Nayak, M.D., Ph.D., chief medical officer for a
multinational technology company, to the company’s board of directors.
“Dr. Nayak’s passion for improving patient care through innovation and
her diverse experience as a physician, scientist, inventor and investor
will be a tremendous asset to Sage,” said Jeff Jonas, M.D., chief
executive officer at Sage. “Her ability to make data-driven decisions
and unique expertise in corporate strategy, development and operations
will be invaluable as we work towards our goal of becoming a commercial
Dr. Nayak currently serves as chief medical officer at Intel Corporation
where she guides its healthcare investment strategy and provides
clinical and business leadership to Intel’s broad spectrum of healthcare
programs. Dr. Nayak served as co-principal investigator on four clinical
studies that demonstrated the value of Intel technologies in the areas
of oncology and preventative cardiology.
“With multiple advanced candidates in clinical trials, this is an
exciting time for Sage,” said Dr. Nayak. “I look forward to working with
the Board and leadership team to achieve Sage’s mission of developing
and delivering new medicines to transform the lives of patients facing
life-altering central nervous system disorders.”
Dr. Nayak’s work played a seminal role in the development of brain MRI
for stroke diagnosis in addition to multiple interventional cardiology
tools in use today. Before joining Intel, she was vice president at New
Leaf Venture Partners, guiding its investments in the medical device
sector. Earlier, Dr. Nayak created and led several new therapy programs
at Medtronic. Now, and throughout her career, Dr. Nayak maintains an
active clinical practice at the Stanford VA emergency department. She is
the inventor on numerous patents and is published in several textbooks
and peer-reviewed journals.
Dr. Nayak holds an M.D. and Ph.D. in neuroscience from the University of
Colorado and completed internal medicine residency and Biodesign
Innovation Fellowship programs at Stanford University.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering central nervous system (CNS) disorders. Sage
has a portfolio of novel product candidates targeting critical CNS
receptor systems, GABA and NMDA. Sage's lead program, brexanolone
(SAGE-547), is in Phase 3 clinical development for postpartum
depression. Sage is developing its next generation modulators, including
SAGE-217 and SAGE-718, in various CNS disorders. For more information,
please visit www.sagerx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171108005077/en/
Source: Sage Therapeutics, Inc.
Suda Communications LLC
Maureen L. Suda,